

News Release

Company name: H.U. Group Holdings, Inc.
Representative: Shigekazu Takeuchi, Chairman,
President and Group CEO
Securities code: 4544 Prime Market, Tokyo Stock
Exchange

Fujirebio Extends its Alzheimer's Disease Test with the Fully Automated Lumipulse® G pTau 217 Plasma Assays for Research Use Only

Tokyo, Japan, December 25, 2023 – H.U. Group Holdings, Inc. and its wholly-owned subsidiary Fujirebio today announced the availability of the Lumipulse G pTau 217 (Tau phosphorylated at threonine 217) plasma assay for the fully automated LUMIPULSE G Systems. This CLEIA (chemiluminescent enzyme immunoassay) assay allows for the quantitative measurement of pTau 217 in human plasma within just 35 minutes. The new automated blood-based biomarker assays are available for Research Use Only.

The plasma pTau 217 is expected as a promising biomarker for differentiating between Alzheimer's disease (AD) and non-AD neurodegenerative diseases and predicting progression to AD.

The new biomarker test will allow researchers and clinical research professionals across the world to further study the clinical utility of pTau 217 quantification in Alzheimer's disease and related disorders on the LUMIPULSE G platform that has the required throughput and meets the regulatory requirements to support possible future routine use.

For details, [see the press release from Fujirebio.](#)

Contacts:

For media:

Public Relations Section, Public Relations/Sustainability Dept.

Phone: +81-3-6279-0884

E-mail: pr@hugp.com

For investors and analysts:

IR/SR Dept.

Phone: +81-3-6279-0926

E-mail: ir@hugp.com